Matinas BioPharma Hldgs (AMEX:MTNB) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.03) by 33.33 percent. This is a 33.33 percent increase over losses of $(0.03) per share from the same period last year.
Matinas BioPharma Hldgs Q2 EPS $(0.02) Beats $(0.03) Estimate
Matinas BioPharma Hldgs (AMEX:MTNB) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.03) by 33.33 percent. This is a 33.33 percent increase over losses of $(0.03) per share
Related Posts
Berenberg Downgrades Grand Canyon Education to Hold, Announces $86 Price Target
Today, 7:45 AM
Berenberg analyst Phillip Leytes downgrades Grand Canyon Education (NASDAQ:LOPE) from Buy to Hold and announces $86 price target.
Reuters Reported Earlier: India Plans To Ask Smartphone Makers To Allow Removal Of Pre-Installed Apps
Today, 7:45 AM
https://www.reuters.com/technology/india-plans-new-security-testing-smartphones-crackdown-pre-installed-apps-2023-03-14/